Of these, the RAS–MAPK constitutes the most frequently affected pathway: up to 90–95% of PC present with activating KRAS mutations and alternative RAS-MAPK pathway alterations are seen in ≈60% of KRAS wild-type tumours [18,20]. Here, KRAS is linked to pachyonychia congenita.